RecruitingHepatocellular Carcinoma

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

22 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Sponsor: AstraZeneca

You may qualify if…

✓ Locally advanced or metastatic and/or unresectable HCC
✓ WHO/ECOG performance status of 0 or 1
✓ BCLC stage B (that is not eligible for locoregional therapy) or stage C.
✓ Child-Pugh Score class A
✓ At least one measurable target lesion
✓ Participants with active HBV infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.
✓ Participants with active HCV infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.
✓ Adequate organ and bone marrow function measured during the screening period.

You may not qualify if…

✕ Medical condition
✕ Any evidence of uncontrolled intercurrent diseases
✕ Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
✕ History of another primary malignancy
✕ Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
✕ Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.
✕ History of active primary immunodeficiency or active infection
✕ History of hepatic encephalopathy